![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1514325
¼¼°èÀÇ Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ ½ÃÀå : ÇöȲ ºÐ¼® ¹× ¿¹Ãø(2024-2032³â)Absorbable Antibacterial Envelope Market: Current Analysis and Forecast (2024-2032) |
Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ(Absorbable Antibacterial Envelope) ½ÃÀåÀº ¾à 5%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÁÖ·Î ½ÉÇ÷°ü ÁúȯÀÇ Ä¡·á¿¡¼ ¿¬±¸°³¹ßÀÇ Áö¼ÓÀûÀÎ °³¼±ÀÌ ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù, Aziyo Biologics, Inc.´Â À̽ÄÇü ÀüÀÚ±â±â(IED)¿ë Â÷¼¼´ë »ýüÀç·á ¿£º§·ÎÇÁÀÎ CanGaroo RM Ç×±Õ ¿£º§·ÎÇÁ¿¡ ´ëÇØ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)¿¡ 510(k) ½ÃÆÇÀü ½Å°í¸¦ ½Ç½ÃÇß½À´Ï´Ù. Aziyo Biologics´Â »ó¾÷ ´Ü°èÀÇ Àç»ý ÀÇ·á ±â¾÷ÀÌ¸ç ´ÙÀ½°ú °°Àº Ư¡ÀûÀÎ Á¦Ç°À» °³¹ßÇÏ°í ¼ö¼ú ȯÀÚÀÇ °á°ú¸¦ Çâ»ó½ÃŰ´Â µ¥ Àü³äÇϰí ÀÖ½À´Ï´Ù.
À¯Çüº°·Î º¼ ¶§ ½ÃÀåÀº ½ÉÀå À絿±â Ä¡·á Á¦¼¼µ¿±â(CRT-D)¿Í À̽ÄÇü Á¦¼¼µ¿±â(ICD)·Î ±¸ºÐµË´Ï´Ù. ½ÉÀå À絿±â ¿ä¹ý Á¦¼¼µ¿±â(CRT-D) Ä«Å×°í¸®´Â ÀåÄ¡¿Í °ü·ÃµÈ °¨¿°ÀÇ ¿ì·Á Áõ°¡¿¡ ´ëÀÀÇÔÀ¸·Î½á Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ ½ÃÀå¿¡¼ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. CRT-D´Â ½É°¢ÇÑ ½ÉºÎÀü ȯÀÚ¿¡°Ô »ç¿ëµÇ±â ¶§¹®¿¡ ICD ¹× Ç¥ÁØ ÆäÀ̽º¸ÞÀÌÄ¿º¸´Ù º¹ÀâÇϰí À̽ÄÇÏ´Â µ¥ ½Ã°£ÀÌ ¿À·¡ °É¸®¹Ç·Î °¨¿°À» ÇÇÇϱâ À§ÇØ Æ¯º°ÇÑ Á¶Ä¡°¡ ÇÊ¿äÇÕ´Ï´Ù. Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁÀÇ °æ¿ì, ÀåÄ¡ÀÇ À̽ĺΠÁÖº¯¿¡ Á¸ÀçÇÒ ¼ö ÀÖ´Â °¨¿° À§ÇèÀ» ÁÙÀ̱â À§ÇؼÀÔ´Ï´Ù. ȯÀÚÀÇ ¾ÈÀü¼º Çâ»ó°ú CRT-D ÀåÄ¡ÀÇ È¿À² Çâ»óÀº ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ »ç¿ë·®À» Áõ°¡½ÃÄÑ Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãŵ´Ï´Ù. À̰ÍÀÌ ÀÌ ºÐ¾ß¿¡¼ °³¹ßÀÇ ÁøÀü¿¡ ÀÖ¾î¼ ½ÉÀå ÀåÄ¡¿Í °¨¿° Á¦¾î ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÇ Á¶ÇÕÀÌ ¸Å¿ì Áß¿äÇÑ ÀÌÀ¯ÀÔ´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î º¼ ¶§ ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ³ª´¹´Ï´Ù. ÀÌ Áß º´¿øÀº 2023³â ±Ý¾× ±âÁØÀ¸·Î ¼¼°è ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. À̰ÍÀº ÁÖ·Î º´¿øÀÌ È¯ÀÚ °ü¸® ±âÁØÀ» ¼³Á¤ÇÏ°í ½ÉÀå ÀåÄ¡ À̽Ŀ¡¼ °¨¿°À» ¹æÁöÇϱâ À§ÇØ Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁÀÇ »ç¿ëÀ» ±ÇÀåÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, º´¿ø¿¡¼ ÀÓÇöõÆ® ¼ö¼ú °Ç¼ö Áõ°¡¿Í ÀÌ·¯ÇÑ Ä¡·á¿¡ ´ëÇÑ ´õ ³ªÀº ±âÁذú ǰÁú¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ÀÌ·¯ÇÑ ºÀÅõÀÇ »ç¿ë·üÀ» ´õ¿í ³ô¿©ÁÝ´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿ä¼Ò´Â º´¿ø ³×Æ®¿öÅ© ¹× ±×·ì ±¸¸Å Á¶Á÷ÀÌ °ø±Þ¾÷ü°¡ Á¦°øÇÏ´Â Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ¸¦ °ü·Ã Á¶Á÷ Àüü¿¡¼ »ç¿ëÇϴ ǥÁØÈ µÈ ÀýÂ÷¸¦ äÅÃÇÏ¿© ±Ô¸ðÀÇ °æÁ¦¸¦ ´Þ¼ºÇÕ´Ï´Ù. ±×¸®°í ½ÃÀåÀÇ Æ÷ȵµ¸¦ È®´ëÇÏ´Â °ÍÀÔ´Ï´Ù.
Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ ½ÃÀå µµÀÔ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇØ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì), À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾Æ ÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ ¹× ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç) ¹× ±âŸ Áö¿ª¿¡¼ ¼¼°èÀÇ Á¸À縦 ±â¹ÝÀ¸·Î ºÐ¼®µË´Ï´Ù. ±× Áß¿¡¼µµ ºÏ¹ÌÀÇ Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ ½ÃÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·üÀÇ ³ôÀÌ¿Í ½ÉÀå µð¹ÙÀ̽ºÀÇ ÀÌ½Ä °Ç¼ö Áõ°¡¿¡ ÀÇÇØ Å« ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ Ã·´Ü ÀÇ·á ÀÎÇÁ¶ó´Â °·ÂÇÑ ±ÔÁ¦ Áö¿ø°ú »ó´çÇÑ ÀÇ·áºñ¿Í ÇÔ²² Èí¼ö¼º Ç×±Õ ¿£º§·ÎÇÁ¿Í °°Àº Çõ½ÅÀûÀÎ ÀÇ·á ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç¿Í Áö¼ÓÀûÀÎ R&D Ȱµ¿ÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á Ä¡·á¿¡¼ °¨¿° ¿¹¹æÀÇ Á߿伺¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í ÷´Ü ÀÇ·á ±â¼úÀÇ Ã¤Åõµ ºÏ¹Ì ½ÃÀåÀÇ ÁøÀüÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
The absorbable antibacterial envelope market concerns the manufacture and use of distinct, biodegradable pouches for containment of cardiovascular and other implantable devices, like pacemakers and defibrillators, which release antimicrobial substances to protect against infection. This market is influenced by several factors, such as a rising rate of cardiac ailments, innovations in biomedical equipment, and a heightened concern over hospital-acquired illnesses. For instance, it is estimated that a heart attack happens within every 40 seconds in the United States and each year, 805,000 people in the United States suffer a heart attack based on the CDC report updated in October 2022. An increasing incidence and implantation of cardiac devices, along with the need for new and effective anti-infective strategies in device use, offers market promotion. Also, the availability of favorable government policies, a rise in healthcare expenditure, and the use of advanced medical solutions in developing countries help to drive the solid growth of the market.
The market for absorbable antibacterial envelope market is set to exhibit a growth rate of about 5%. This is mainly due to the continuous improvements in research and development in the treatment of cardiovascular diseases driving the demand of the market. For instance, in April 2022, Aziyo Biologics, Inc. filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo RM antibacterial envelope, its next-generation biomaterial envelope for use with implantable electronic devices (IED). Aziyo Biologics is a commercial-stage regenerative medicine firm dedicated to developing the following line of distinctive products and enhancing surgical patient outcomes.
Based on type, the market is segmented into cardiac resynchronization therapy defibrillators (CRT-D) and implantable cardioverter defibrillators (ICD). The cardiac resynchronization therapy defibrillators (CRT-D) category is expected to have the largest market share of the absorbable antibacterial envelope market by addressing the rising concerns of device-related infections. CRT-D devices are used for patients with severe heart failure and hence, need some extra measures to avoid infections because of their complexity and longer implantation times than required for ICDs or standard pacemakers. As for the absorbable antibacterial envelopes, it is to reduce infection risks that may be around the area of implantation of the device. Improved patient safety and increased efficiency of the CRT-D devices lead to increased usage of these devices, hence the demand for absorbable antibacterial envelopes. That is the reason why the combination of cardiac devices with the need for infection control solutions is crucial in developmental progression within this sector.
Based on end-user, the market has been divided into hospitals, ambulatory surgical centers (ASCs), and others. Among them, the hospitals were leading the global market in terms of value in 2023. This is mainly because hospitals set standards for patient care, encouraging the use of absorbable antibacterial envelopes to prevent infections in cardiac device implantations. Furthermore, the increasing number of implant surgeries in hospitals, integrated with an increased focus on better standards and quality in these procedures, further the usage rate of these envelopes. Another important factor that contributes to the market growth is the role of hospital networks or group purchasing organizations as they adopt standardized procedures of using absorbable antibacterial envelopes provided by the vendors across their affiliated organizations, achieving economies of scale, and expanding the market saturation.
For a better understanding of the market adoption of absorbable antibacterial envelope, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Among them, the North American absorbable antibacterial envelope market is poised for significant growth, driven by the high prevalence of cardiovascular diseases and the increasing number of cardiac device implantations. The region's advanced healthcare infrastructure, coupled with strong regulatory support and substantial healthcare spending, facilitates the adoption of innovative medical solutions like absorbable antibacterial envelopes. Additionally, the presence of major market players and ongoing research and development activities further contribute to market expansion. Rising awareness about the importance of infection prevention in medical procedures and the adoption of advanced healthcare technologies also propel the market forward in North America.
Some of the major players operating in the market include Medtronic and Elutia.